CRI-Vac

CRI-Vac is a biotechnology company focused on developing a novel cancer vaccine platform based on bacterial outer membrane vesicles (OMVs). The company's technology utilizes bioengineered OMVs to deliver tumor-specific antigens and immunostimulatory molecules directly to the immune system, aiming to trigger a robust and targeted anti-tumor response. By leveraging the natural immunogenicity of bacterial vesicles, CRI-Vac seeks to overcome the limitations of traditional peptide-based vaccines. The platform is designed to be modular, allowing for the rapid development of personalized or shared-antigen cancer therapies across various solid tumor indications.